Castle Biosciences, Inc.CSTLNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank52
3Y CAGR+5.1%
5Y CAGR-38.8%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+5.1%/yr
vs -35.1%/yr prior
5Y CAGR
-38.8%/yr
Recent acceleration
Acceleration
+40.2pp
Accelerating
Percentile
P52
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 4.28% |
| Q3 2025 | 1.35% |
| Q2 2025 | 1.58% |
| Q1 2025 | 7.80% |
| Q4 2024 | -5.24% |
| Q3 2024 | -12.83% |
| Q2 2024 | 2.37% |
| Q1 2024 | 6.27% |
| Q4 2023 | 0.55% |
| Q3 2023 | -2.89% |
| Q2 2023 | -7.54% |
| Q1 2023 | 27.27% |
| Q4 2022 | 3.69% |
| Q3 2022 | -8.54% |
| Q2 2022 | 10.83% |
| Q1 2022 | 13.93% |
| Q4 2021 | 25.93% |
| Q3 2021 | 10.41% |
| Q2 2021 | 14.98% |
| Q1 2021 | 28.97% |
| Q4 2020 | 49.80% |
| Q3 2020 | 13.09% |
| Q2 2020 | -7.17% |
| Q1 2020 | -7.79% |
| Q4 2019 | 108.52% |
| Q3 2019 | 15.01% |
| Q2 2019 | -5.50% |
| Q1 2019 | 22.48% |
| Q4 2018 | -12.07% |
| Q3 2018 | 11.65% |
| Q2 2018 | -8.20% |
| Q1 2018 | 0.00% |